Glenmede Trust Co. NA Decreases Stake in Praxis Precision Medicines, Inc. $PRAX

Posted by Stanley Muller on Aug 7th, 2026

Glenmede Trust Co. NA cut its position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 45.8% in the first quarter, Holdings Channel.com reports. The institutional investor owned 3,410 shares of the company’s stock after selling 2,878 shares during the period. Glenmede Trust Co. NA’s holdings in Praxis Precision Medicines were worth $1,099,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Janus Henderson Group PLC increased its stake in Praxis Precision Medicines by 6.8% in the 1st quarter. Janus Henderson Group PLC now owns 3,458,863 shares of the company’s stock worth $1,113,514,000 after acquiring an additional 218,777 shares during the last quarter. Perceptive Advisors LLC boosted its position in shares of Praxis Precision Medicines by 27.6% during the 4th quarter. Perceptive Advisors LLC now owns 1,995,986 shares of the company’s stock valued at $588,297,000 after acquiring an additional 431,432 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Praxis Precision Medicines by 13.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,974,585 shares of the company’s stock valued at $83,031,000 after acquiring an additional 231,827 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Praxis Precision Medicines by 15.3% in the fourth quarter. Vanguard Group Inc. now owns 1,460,933 shares of the company’s stock valued at $430,595,000 after purchasing an additional 193,647 shares in the last quarter. Finally, Orbis Allan Gray Ltd bought a new stake in Praxis Precision Medicines in the fourth quarter worth $369,946,000. Hedge funds and other institutional investors own 67.84% of the company’s stock.

Praxis Precision Medicines Stock Performance

NASDAQ:PRAX opened at $370.16 on Friday. The firm has a market capitalization of $10.32 billion, a PE ratio of -27.69 and a beta of 2.78. The stock’s fifty day moving average is $303.77 and its 200 day moving average is $315.47. Praxis Precision Medicines, Inc. has a fifty-two week low of $37.19 and a fifty-two week high of $382.54.

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($2.87) EPS for the quarter, topping the consensus estimate of ($3.67) by $0.80. Equities analysts forecast that Praxis Precision Medicines, Inc. will post -14.82 EPS for the current year.

Insider Activity

In other news, Director Jill Desimone sold 11,600 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $311.32, for a total value of $3,611,312.00. Following the completion of the sale, the director owned 2,337 shares in the company, valued at approximately $727,554.84. This trade represents a 83.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Piper Sandler reaffirmed an “overweight” rating on shares of Praxis Precision Medicines in a research note on Monday, July 13th. Jefferies Financial Group reissued a “buy” rating on shares of Praxis Precision Medicines in a research note on Thursday, May 7th. BTIG Research restated a “buy” rating and issued a $810.00 target price on shares of Praxis Precision Medicines in a report on Wednesday, July 29th. Robert W. Baird decreased their target price on shares of Praxis Precision Medicines from $433.00 to $400.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 2nd. Finally, Truist Financial set a $616.00 price target on shares of Praxis Precision Medicines and gave the company a “buy” rating in a report on Tuesday, June 2nd. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $563.85.

Read Our Latest Research Report on Praxis Precision Medicines

Praxis Precision Medicines Company Profile

(Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.